Keenova Therapeutics plc·4

Nov 12, 8:00 PM ET

Welch Stephen Andrew 4

4 · Keenova Therapeutics plc · Filed Nov 12, 2025

Insider Transaction Report

Form 4
Period: 2025-11-10
Welch Stephen Andrew
EVP & Head of Spec Generics
Transactions
  • Disposition to Issuer

    Restricted Stock Units

    2025-11-10+43,7710 total
    Ordinary Shares (43,771 underlying)
Footnotes (1)
  • [F1]These restricted units were cancelled in connection with the separation of Par Health, Inc. ("Par Health") from the Issuer in exchange for a number of restricted units of Par Health calculated pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.

Documents

1 file
  • 4
    tm2531021-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT